Thromboprophylaxis and thrombosis in medical, surgical, trauma, and obstetric/gynecologic patients

Hematology/Oncology Clinics of North America

Volumn 17, Issue 1, 2003, Pages 217-258

  Bick, Rodger L ^a,b,c   Haas, Sylvia ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Dallas Thromb Hemostasis Clin Ctr   (United States)

^c ThromboCare Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DALTEPARIN; DEXTRAN; ENOXAPARIN; HEPARIN; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARM EXERCISE; ARTHROSCOPIC SURGERY; BLEEDING; CESAREAN SECTION; CLINICAL TRIAL; COMPRESSION THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; GENE MUTATION; HEALTH CARE COST; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; JOINT PROSTHESIS; LEG COMPRESSION; LEG EXERCISE; LUNG EMBOLISM; META ANALYSIS; NEUROSURGERY; OCCLUSIVE CEREBROVASCULAR DISEASE; ORAL CONTRACEPTION; ORTHOPEDIC SURGERY; PRACTICE GUIDELINE; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SURGICAL PATIENT; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT;

ANTICOAGULANTS; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; OBSTETRIC SURGICAL PROCEDURES; POSTOPERATIVE COMPLICATIONS; THROMBOSIS; WOUNDS AND INJURIES;

EID: 0037321298     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(02)00100-4     Document Type: Review

References (120)

1. Bick RL, Fareed J. Current status of thrombosis: a multidisciplinary medical issue and major American health problem - beyond the year 2000. Clin Appl Thromb Hemost 1997;3(Suppl 1):1.
2. Heart and stroke - 1997. Dallas: American Heart Association National Headquarters; 1996.
3. Bick RL, Kaplan H. Syndromes of thrombosis and hypercoagulability: congenital and acquired causes of thrombosis. Med Clin North Am 1998;82:409.
4. Bick RL, Jakway J, Baker WF. Deep vein thrombosis: prevalence of etiologic factors and results of management in 100 consecutive patients. Semin Thromb Hemost 1992;18:267.
5. Bergqvist D, Lundblad B. Incidence of venous thromboembolism in medical and surgical patients. In: Bergqvist D, Comerota A, Nicolaides A, Scurr J, editors. Prevention of venous thromboembolism. London: Med-Orion Press; 1994 [chapter 1].
6. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intent Med 1998;158:585.
7. Ramaswami G, Nicolaides AN. The natural history of deep vein thrombosis. In: Bergqvist D, Comerota A, Nicolaides A, Scurr J, editors. Prevention of venous thromboembolism. London: Med-Orion Press; 1994 [chapter 10].
8. Bick RL. Proficient and cost effective approaches for the prevention and treatment of venous thrombosis and thromboembolism. Drugs 2000;60:575.
9. Bick RL, Ancypa D. Blood protein defects associated with thrombosis: laboratory assessment. Clin Lab Med 1995;15:125.
10. MedPar. The MedStat Group outcomes analysis. Nashville: Inforum, Medistat; 1998.
11. DeStefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes and management. Blood 1996;87:3531.
12. Bick RL. Sticky platelet syndrome: a common cause of unexplained venous and arterial thrombosis - results of prevalence and treatment outcome. Clin Appl Thromb Hemost 1998;4:1.
13. Mammen EF. Sticky platelet syndrome. Semin Thromb Hemost 1999;24:361.
14. Bick RL, Baker WF. The antiphospholipid thrombosis syndrome and thrombosis. Semin Thromb Hemost 1999;25:333.
15. Bick RL. Antiphospholipid thrombosis syndromes: etiology, pathophysiology, diagnosis and management. Int J Hematol 1997;65:193.
16. Bick RL. Therapy for venous thrombosis: guidelines for a competent and cost-effective approach. Clin Appl Thromb Hemost 1999;5:2.
17. Bick RL, Hinton RC. Prevalence of hereditary and acquired coagulation protein/platelet defects in patients with cerebral ischemic events. Blood 1998;92(Suppl 1, Part 2):114.
18. Bick RL. Syndromes of thrombosis and hypercoagulability: congenital and acquired thrombophilias. Clinical Applied Thrombosis Hemostasis 1998;4:25.
19. Beyth RJ, Cohen AM, Landefeld CS. Long-term outcomes of deep-vein thrombosis. Arch Intern Med 1995;155:1031.
20. Prandoni P, Lensing AWA, Cogo A, Cuppini S, Villalta S, Carta M, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1.
21. Marshall J, Tu D. Dalteparin: a low molecular weight heparin. PHD Pharmacy Letter 1998;16:5.
22. Ardeparin and danaparoid for prevention of deep vein thrombosis. The Medical Letter 1997;39:94.
23. Bick RL, Haas SK. International consensus recommendations: Summary statement and additional suggested guidelines. Med Clin North Am 1998;83:613.
24. American College of Chest Physicians. Conference on Antithrombotic Therapy. Chest 1986;89:1.
25. European consensus statement on the prevention of venous thromboembolism. Int Angiol 1992; 11:151.
26. Treatment of venous thrombosis and pulmonary embolism. In: Waersted A, Westbye O, Beermann B, Strandberg K, editors. Norwegian medicines control authority, Oslo, Norway. Uppsala (Sweden): Medical Products Agency; 1995.
27. Prevention of venous thromboembolism. International consensus statement (guideline according to scientific evidence). Int Angiol 1997;16:3.
28. McIntyre K. Medicolegal implications of consensus statements. Chest 1995;108:502.
29. Hull RD, Pineo GF. Prophylaxis of deep venous thrombosis and pulmonary embolus: current recommendations. Med Clin North Am 1998;82:477.
30. Dismuke SE, Wagner EH. Pulmonary embolism as a cause of death: the changing mortality in hospitalized patients. JAMA 1986;255:2039.
31. Dalen JE, Alpert JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis 1975; 17:257.
32. Baker WF. Diagnosis of deep venous thrombosis and pulmonary embolism. Med Clin North Am 1998;82:459.
33. Anderson FA, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. Arch Intern Med 1991;151:933.
34. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients: results of meta-analysis. Ann Surg 1988;208:227.
35. Collins R, Scrimgeour A, Yusef S, et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. N Engl J Med 1988; 318:1162.
36. Nicolaides AN (and committee). Prevention of venous thromboembolism. International consensus statement - guidelines compiled in accordance with scientific evidence. Int Angiol 2001;20:3.
37. Nicolaides AN. Prevention of thromboembolism: international consensus statement. In: Bergqvist D, Comerota AJ, Nicolaides AN, Scurr JH, editors. Prevention of venous thromboembolism. Los Angeles: Med-Orion Publishing; 1994. p. 445 [chapter 41].
38. Bratzler DW, Raskob GE, Murray CK, Piatt DS. Underuse of venous thromboembolism prophylaxis for general surgery patients. Arch Intern Med 1998;158:1909.
39. Gillies TE, Ruckley CV, Nixon SJ. Still missing the boat with fatal pulmonary embolism. Br J Surg 1996;83:1394.
40. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001; 119:132S-75S.
41. Kleber FX, Witt C, Flosbach CW, Koppenhagen K, Vogel G, the Prince Study Group. Comparison of the low molecular weight heparin enoxaparin with unfractionated heparin in the prevention of venous thromboembolic events in medical patients with severe cardiopulmonary disease [abstract]. Thromb Haemost 1999;82(Suppl):1552.
42. Kher A, Samama MM. Low-molecular-weight heparins: weeks or months instead of days of treatment. J Clin Appl Thrombos Hemost 2001;7(4):314-20.
43. Goldhaber S. Venous thromboembolism prophylaxis in medical patients. Thromb Haemost 1999;82(Suppl):899.
44. Mismetti P, Laporte-Simitsidis S, Tardy B, Cucherat M, Buchmüller A, Juillard-Delsart D, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000;83:14.
45. Nicolaides AN, Bergqvist D, Hull R. Prevention of venous thromboembolism: international consensus statement (guideline according to scientific evidence). Int Angiol 1997;16:3.
46. Hillbom M, Erilä T, Flosbach CW, Sataniemi K, Tatlisumak T, Sama S, et al. Enoxaparin, a low molecular weight heparin, is superior to heparin in the prevention of deep vein thrombosis in patients with acute atherothrombotic stroke [abstract]. Thromb Haemost 1999; 89(Suppl):177.
47. Albers GW, Amarebhco P, Easton JD, et al. Antithrombotics and thrombolytic therapy for ischemic stroke. Chest 2001;119(Suppl 1):300S.
48. Samama MM, Cohen AT, Damron JY, Desjardins L, Eldor A, Janbon C, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999;341:793-800.
49. Kakkar VV. Effectiveness and safety of low molecular weight heparins (LMWH) in the prevention of venous thromboembolism. Thromb Haemost 1995;74:364.
50. Haas SK. Treatment of deep venous thrombosis: current recommendations. Med Clin North Am 1998;82:495.
51. Philbrick JT, Becker DM. Calf deep vein thrombosis: a wolf in sheep's clothing? Arch Intern Med 1988;148:2131.
52. Greenfield LJ, Michna BA. Twelve-year clinical experience with the Greenfield vena cava filter. Surgery 1988;104:706.
53. Magnant JG, Walsh DB, Juravsky LI, Cronenwett JL. Current use of inferior vena cava filters. J Vasc Surg 1992;16:701.
54. Descousus H, Leizorocicz A, Parent F, Page Y, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med 1998;338:409.
55. White RH, Zhou H, Kim J, Romano PS. A population-based study of the effectiveness of inferior vena cava filter use among patients with venous thromboembolism. Arch Intern Med 2000;1260:2033.
56. Baker WF, Bick RL. Deep vein thrombosis: diagnosis and management. Med Clin North Am 1994;78:685.
57. Murano G, Bell WR. Thrombolytic therapy. In: Bick RL, Bennett JM, Brynes RK, editors. Hematology: clinical and laboratory practice. St. Louis: Mosby; 1993. p. 1633 [chapter 104].
58. Bell WR. Thrombolytic therapy: agents, indications and laboratory monitoring. Med Clin North Am 1994;78:745.
59. Hoomes DW, Bura A, Mazzolai L, Buller HR, ten Cate JW. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis: a meta-analysis. Ann Intern Med 1992;116:279.
60. Doyle DJ, Turpie AGG, Hirsh J, Best C, Knich D, Levine MN, et al. Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. Ann Intern Med 1987;107:441.
61. Anderson G, Fagrell B, Holmgren K, Johnsson H, Ljungberg B, Nilsson E, et al. Subcutaneous administration of heparin: a randomized comparison with intravenous administration of heparin to patients with deep-vein thrombosis. Thromb Res 1982;27:631.
62. Hull RD, Raskob G, Hirsh J, Jay R, Leclerc J, Geerts W, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal vein thrombosis. N Engl J Med 1986;315:1109.
63. Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA. The importance of initial treatment on long-term outcomes of antithrombotic therapy. Arch Intern Med 1997;157:2317.
64. Walenga JM, Bick RL. Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy. Med Clin North Am 1998;82:635.
65. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997;337:657.
66. Duroux P. A collaborative European multicentre study: a randomized trial of subcutaneous low molecular weight heparin (CY216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1991;65:251.
67. Faivre R, Neuhart Y, Kieffer Y, Apfel F, Magnin D, Didier D, et al. Un nouveau traitement des thromboses veineuses profondes: les fractions d'heparine de bas poids moleculaire. Etude randomisee. Presse Med 1988;17:197.
68. Fiessinger JN, Lopez-Fernandez M, Gatterer E, et al. Once-daily subcutaneous Dalteparin, a low nolecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost 1996;76:195.
69. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992;326:975.
70. Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996;334:682.
71. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deepvein thrombosis. N Engl J Med 1996;334:677.
72. Lindmarker P, Holmstrom M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thromb Haemost 1994;72:186.
73. Lopaciuk S, Meissner AJ, Filipecki S, et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thromb Haemost 1992;68:14.
74. Luomanmaki K, the Finnish multicentre group. Low molecular weight heparin (Fragmin) once daily vs continuous infusion of standard heparin in the treatment of DVT [abstract 248]. Haemostasis 1994;24(Suppl 1):24.
75. Prandoni P, Lensing AWA, Butler HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992;339:441.
76. Simonneau G, Charbonnier B, Decousus H, et al. Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the initial treatment of proximal vein thrombosis. Arch Intern Med 1993;153:1541.
77. Simonneau G, Sors H, Charbonnier B, Page Y, Laaban J-P, Azarian R, et al, for the THESEE Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997;337:663.
78. Heissler FF, Bick RL. Dalteparin for the treatment of deep venous thrombosis and pulmonary embolism. New Developments in Vascular Diseases 2001;2:24-35.
79. van den Belt AGM, Prins MH, Lensing AWA, Castro AA, Clark OAC, Atallah AN, et al. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism (Cochrane review). In: The Cochrane library, issue 2. Oxford: Update Software; 1998.
80. Hull RD, Raskob GE, Pineo GF, Brant RF. The treatment of proximal vein thrombosis with subcutaneous low molecular weight heparin compared with continuous intravenous heparin. The Canadian-American Thrombosis Study Group. Clin Appl Thromb Hemost 1995;1:151.
81. Shafer AI. Low-molecular-weight heparin: an opportunity for home treatment of venous thrombosis [editorial]. N Engl J Med 1996;334:724.
82. Harrison L, McGinnis J, Crowther M, Ginsberg J, Hirsh J. Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med 1998; 158:2001.
83. Wells P, Kovacs M, Bormanis J, Forgic M, Goudic D, Kovacs J. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolus with low-molecular-weight heparin: a comparison of self-injection with homecare injection. Arch Intern Med 1998;158:1809.
84. Verstraete M, Prentice CRM, Samama M, Verhaeghe R, on behalf of a European working group. A European view on the North American Sixth Consensus on Antithrombotic Therapy. Chest 2000;117:1755.
85. Kakkar VV, Adams PC. Preventive and therapeutic approach to venous thromboembolism. Can death from pulmonary embolism be prevented? J Am Coll Cardiol 1986;8:146B.
86. Skinner DB, Salzman EW. Anticoagulant prophylaxis in surgical patients. Surg Gynecol Obstet 1967;125:741.
87. Shephard RM, White HA, Shirkey AL. Anticoagulant prophylaxis of thromboembolism in post-surgical patients. Am J Surg 1966;112:698.
88. International Multicentre Trial. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. Lancet 1975;2:45.
89. Bergqvist D. Prevention in individual patient groups: general surgery. In: Bergqvist D, Comerota AJ, Nicolaides AN, Scurr JH, editors. Prevention of venous thromboembolism. Los Angeles: Med-Orion Publishing; 1994. p. 243 [chapter 23].
90. Coventry MB, Nolan DR, Beckenbaugh RD. "Delayed" prophylactic anticoagulation: a study of results and complications in 2,012 total hip arthroplasties. J Bone Joint Surg 1973;55:1487.
91. Eskeland G, Solheim K, Skhorten F. Anticoagulant prophylaxis, thromboembolism and mortality in elderly patients with hip fracture: a controlled clinical trial. Acta Chir Scand 1986;131:16.
92. Kearon C, Hirsh J. Starting prophylaxis for venous thromboembolism postoperatively. Arch Intern Med 1995;155:366.
93. Palareti G, Borghi B, Coccheri S, for the CITO Study Group. Postoperative versus preoperative initiation of deep-vein thrombosis prophylaxis with a low molecular weight heparin (Nadroparin) in elective hip replacement. Clin Appl Thromb Hemost 1996;2:18.
94. Hull RD, Hirsh J, Carter CJ, et al. Diagnostic efficacy of impedance plethysmography for clinically suspected deep-vein thrombosis: a randomized trial. Ann Intern Med 1985;102:21.
95. Walenga J, Bick RL. Heparin associated thrombocytopenia and other adverse effects of heparin therapy. Cardiol Clin 1998;2:123.
96. Kakkar VV, Cohen AT, Edmonson RA, et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 1993;341:259.
97. Kakkar VV, Boeckl O, Boneau B, et al. Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial. World J Surg 1997;21:2.
98. Bergqvist D, Matzsch T, Brumark U, et al. Low-molecular-weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis. Br J Surg 1988;75:888.
99. Samama M, Bernard P, Bonnardot JP, et al. Low-molecular-weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. Br J Surg 1988;75:128.
100. The European Fraxiparin Study Group. Comparison of a low-molecular-weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. Br J Surg 1988;75:1058.
101. Caen JP. A randomized double-blind study between a low-molecular-weight heparin Kabi 2165 and standard heparin in the prevention of deep-vein thrombosis in general surgery: a French multicentre trial. Thromb Haemost 1988;59:216.
102. Leizorovicz A, Picolet H, Peyrieux JC, et al. Prevention of perioperative deep vein thrombosis in general surgery: a multicentre double-blind study comparing two doses of logiparin and standard heparin. Br J Surg 1991;78:412.
103. Nurmohamed MT, Verhaeghe R, Haas S, et al. A comparative trial of a low molecular weight heparin (Enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery. Am J Surg 1995;169:567.
104. Bergqvist D, Burmark US, Flordal PA, et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 500 Xal units in 2070 patients. Br J Surg 1995;82:496.
105. Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of deep vein thrombosis after major knee surgery:-a randomized, double-blind trial comparing a low-molecular-weight heparin fragment (Enoxaparin) to placebo. Thromb Haemost 1992;67:417.
106. Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of venous thromboembolism after knee arthroplasty: a randomized, double-blind trial comparing a low molecular weight heparin fragment (Enoxparin) to Warfarin [abstract]. Thromb Haemost 1995;73:1103.
107. Heit J, Berkowitz S, Bona R, et al. Efficacy and safety of Normiflow (a LMWH) compared to warfarin for prevention of venous thromboembolism following total knee replacement: a double-blind, dose-ranging study [abstract]. Thromb Haemost 1995;73:A739.
108. Nunnohamed MT, Rosendaal FR, Büller HR, et al. Low molecular weight heparin in the prophylaxis of venous thrombosis: a meta-analysis. Lancet 1992;340:152.
109. Geerts WH, Jay RM, Code KI, et al. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 1996;335:701.
110. Haas S. Recommendations for prophylaxis of venous thromboembolism: international consensus and the American College of Chest Physicians Sixth Consensus Conference on antithrombotic therapy. J Clin Appl Thromb Hemost; in press.
111. Dale C, Gallus A, Wycherley A, et al. Prevention of venous thrombosis with minidose warfarin after joint replacement. BMJ 1991;303:224.
112. Roberts VC, Sabri S, Beely AH, et al. The effect of intermittently applied external pressure on the hemodynamics of the lower limb in man. Br J Surg 1972;59:233.
113. Skillman JJ, Collins RR, Coe NP, et al. Prevention of deep vein thrombosis in neurosurgical patients: a controlled, randomized trial of external pneumatic compression boots. Surgery 1978; 83:354.
114. Ramos R, Salem BI, Pawlikowski MP, et al. The efficacy of pneumatic compression stockings in the prevention of pulmonary embolism after cardiac surgery. Chest 1996;109:82.
115. Hull RD, Raskob G, Gent M, et al. Effectiveness of intermittent pneumatic leg compression for preventing deep vein thrombosis after total hip replacement. JAMA 1990;263:2313.
116. Clagett GP, Anderson FA, Heir J. Prevention of venous thromboembolism. Chest 1995; 108:312S.
117. Turner GM, Cole SF, Brooks JH. The efficacy of graduated compression stockings in the prevention of deep vein thrombosis after major gynecological surgery. Br J Obstet Gynecol 1984;91:588.
118. Sarret M, Kher A, Toulemonde F. Prophylaxis of venous thromboembolism in general, oncological, gynecological and neurological surgery. In: Sarret M, Kher A, Toulemonde F, editors. Low molecular weight heparin. New York: Marcel Dekker; 1999. p. 29-246.
119. Haas SK, Wolf H, Encke A, Fareed J. Prevention of fatal postoperative pulmonary embolism by low molecular weight heparin: a double blind comparison of certoparin and unfractionated heparin [abstract 1548]. Thromb Haemost 1999;82(Suppl):24.
120. Haas S, Turpie AGG. From foundations to the future: building a new era in DVT management. Blood Coagul Fibrinolysis 1999;10(Suppl):S1-131.